Myocardial Infarction Triage and Intervention Project (MITI)
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1988-04-01
To determine the practicality, benefit, and safety of paramedic administration of
thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly
identifying candidates for thrombolytic therapy following myocardial infarction was assessed
in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital
thrombolytic therapy.
Myocardial Infarction Triage and Intervention Project (MITI)
Completed
University of Washington
Phase 3
1988-04-01
To determine the practicality, benefit, and safety of paramedic administration of
thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly
identifying candidates for thrombolytic therapy following myocardial infarction was assessed
in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital
thrombolytic therapy.
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
Completed
Astellas Pharma US, Inc.
Phase 2
2000-12-01
The purpose of this study is to determine if YM872 in combination with t-PA can reduce
disability and brain damage from stroke. YM872 or placebo will be given as a continuous
intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or
placebo, is administered prior to the completion of the t-PA administration. The clinical
effects of YM872 in addition to t-PA will be determined by assessing neurological function
and disability scores at follow up visits through Day 90 of the study.
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
Completed
Astellas Pharma Inc
Phase 2
2000-12-01
The purpose of this study is to determine if YM872 in combination with t-PA can reduce
disability and brain damage from stroke. YM872 or placebo will be given as a continuous
intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or
placebo, is administered prior to the completion of the t-PA administration. The clinical
effects of YM872 in addition to t-PA will be determined by assessing neurological function
and disability scores at follow up visits through Day 90 of the study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
